Abstract
Induction therapy with rabbit anti-thymocyte globulin is preferable to induction with daclizumab in renal transplant recipients at high immunological risk. These findings provide additional support to the idea that personalized immunosuppressive regimens should be developed in renal transplant recipients.
MeSH terms
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized
-
Antilymphocyte Serum / therapeutic use*
-
Daclizumab
-
Graft Rejection / drug therapy*
-
Graft Rejection / epidemiology
-
Humans
-
Immunoglobulin G / therapeutic use
-
Immunosuppressive Agents / therapeutic use*
-
Incidence
-
Kidney Transplantation*
-
Precision Medicine / methods*
-
Risk Factors
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antilymphocyte Serum
-
Immunoglobulin G
-
Immunosuppressive Agents
-
Daclizumab